Cancer

If you have the JAK2 V617F mutation, are aged 18-74 years old, do not smoke, do not have any known autoimmune disease, and attend medical checks at UAB regularly, you may be eligible for our study! This study focuses on better understanding how diet influences quality of life in MPN patients. We will test whether an anti-inflammatory food regime can help alleviate symptoms and decelerate disease progression. Participants will meet with study staff to collect non-invasive samples, undergo anthropometric and metabolic measurements, and answer study related questionnaires. Samples to be collected include blood and stool samples. Participants will be compensated $50 for each visit and providing samples if simply continuing their regular food intake, or $90 each month if trying an anti-inflammatory food regime for 3 months and completing the study visits and providing samples. Participants who adhere to an anti-inflammatory regime and would like to continue a further 9 months may be eligible to continue participating with a compensation of $90 per month. Study participants in all groups would receive information related to body inflammation, vitamin D levels, and metabolism if desired. Total maximum compensation of $150, $270 and $810 depending on study group. For more information, please contact us via phone or email at Phone: 205-975-3752, Email addresses: tmarquezlago@uabmc.edu or mpn@uabmc.edu.

Do you identify as an individual living with cancer and part of the LGBTQIA+ community or a care partner of someone in this community? A research lab at the University of Alabama at Birmingham is looking to learn about the day-to-day experiences of LGBTQIA+ cancer survivors and their care partners. We are interested in how individuals manage difficult situations related to their respective roles in their relationships. Individuals living with cancer often encounter stressful situations that can impact their mood and any additional stressors from living as a sexual or gender minority with a lack of resources adds an increased risk of experiencing stressful situations. The goal of this work is to develop resources that better support the well-being of LGBTQIA+ individuals living with cancer and their care partners. This study will take place FULLY online with completion of daily surveys. All participants will be compensated. To learn more about our study contact us at starlab@uab.edu.

Clinical trial evaluating a novel, non-invasive radiation treatment for ventricular tachycardia refractory to medication and catheter ablation The UAB Departments of Radiation Oncology and Cardiology are looking for patients with ventricular tachycardia (VT) not controlled by medications and catheter ablation. The trial will allow patients suffering from VT despite standard of care regimens to undergo non-invasive cardiac radioablation (CRA; a type of stereotactic body radiotherapy) to the area of the heart responsible for their symptoms. Stereotactic body radiotherapy is delivered with a device called the linear accelerator, which is primarily used to treat patients with cancer. UAB is one of the first centers in the U.S. to obtain a Food and Drug Administration (FDA) investigational device exemption for use of the linear accelerator in this capacity on a phase I/II trial. The study is being conducted in collaboration with the Washington University School of Medicine in St. Louis, a center which pioneered this promising technique in the U.S. For more information on the RAD 1901 trial, please contact Adelyn Gillon, clinical research coordinator, at 205.975.3019 or agillon@uabmc.edu.